Clinicians frequently shorten venetoclax duration to 14 or 21 days to help patients recover blood counts and avoid treatment delays caused by azacitidine-venetoclax combinations. However, the OPTI-AML study—which enrolled 169 patients aged 60 and older—found that the 14-day schedule failed to meet noninferiority criteria. Complete remission rates reached 49.4% for the 28-day group, compared to 43% for those on the shortened cycle.
Shortened Venetoclax Regimens Fail to Match Standard AML Treatment
A 14-day venetoclax schedule does not offer equivalent efficacy to the standard 28-day regimen for older patients with newly diagnosed acute myeloid leukemia, according to results from the Beat AML Master Clinical Trial published in Blood. The findings challenge common clinical practices aimed at mitigating treatment-related toxicity.
Lead author Uma Borate of the OSUCCC – James emphasized that reducing treatment intensity is not a universal solution. The data indicates that outcomes are linked to disease biology; patients with NPM1 or IDH2 mutations saw significantly higher remission rates with the full 28-day course. These results suggest that future treatment protocols must move toward personalized dosing rather than blanket reductions, especially as researchers begin testing new triplet therapies in addition to standard regimens.
Comments (0)
No comments yet. Be the first!